CG
ABBV icon

Corundum Group’s AbbVie ABBV Stock Holding History

Corundum Group’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.01M Sell
8,000
-55
-0.7% -$11.8K 0.6% 39
2026
Q1 		$1.75M Sell
8,055
-256
-3% -$56.8K 0.59% 37
2025
Q4 		$1.9M Buy
8,311
+813
+11% +$185K 0.64% 31
2025
Q3 		$1.74M Sell
7,498
-22
-0.3% -$4.48K 0.71% 32
2025
Q2 		$1.4M Buy
7,520
+2,391
+47% +$444K 0.62% 34
2025
Q1 		$1.07M Sell
5,129
-4,052
-44% -$788K 0.52% 47
2024
Q4 		$1.63M Buy
9,181
+4,159
+83% +$765K 0.61% 48
2024
Q3 		$992K Sell
5,022
-4,211
-46% -$786K 0.45% 52
2024
Q2 		$1.58M Buy
9,233
+4,367
+90% +$723K 0.62% 45
2024
Q1 		$886K Sell
4,866
-102
-2% -$17.6K 0.43% 54
2023
Q4 		$770K Buy
4,968
+106
+2% +$15.5K 0.39% 54
2023
Q3 		$725K Sell
4,862
-873
-15% -$128K 0.41% 56
2023
Q2 		$773K Sell
5,735
-4,295
-43% -$630K 0.39% 61
2023
Q1 		$1.6M Buy
10,030
+3,526
+54% +$539K 0.76% 37
2022
Q4 		$1.05M Buy
6,504
+120
+2% +$18.4K 0.59% 43
2022
Q3 		$857K Buy
6,384
+898
+16% +$129K 0.54% 45
2022
Q2 		$840K Buy
5,486
+100
+2% +$15.3K 0.57% 45
2022
Q1 		$873K Buy
5,386
+143
+3% +$20.8K 0.81% 45
2021
Q4 		$710K Buy
5,243
+547
+12% +$64.6K 0.46% 42
2021
Q3 		$507K Buy
4,696
+488
+12% +$55.8K 0.38% 41
2021
Q2 		$474K Buy
4,208
+57
+1% +$6.42K 0.31% 45
2021
Q1 		$449K Buy
4,151
+87
+2% +$9.31K 0.35% 44
2020
Q4 		$435K Buy
4,064
+325
+9% +$31.2K 0.36% 41
2020
Q3 		$327K Buy
3,739
+231
+7% +$21.7K 0.32% 44
2020
Q2 		$344K Buy
+3,508
New +$309K 0.41% 30

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Corundum Group's ABBV Position: Q2 2026 in Review

Corundum Group reduced its AbbVie (ABBV) stake by 0.68% in Q2 2026, selling an estimated $11.8K and leaving 8,000 shares worth $2.01M. The position accounts for 0.6% of the portfolio, ranked #39.

Corundum Group first reported a position in ABBV in Q2 2020 and has held it in 25 quarters since. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Corundum Group held 8,000 shares of AbbVie worth $2.01M as of Q2 2026.
  • Corundum Group sold 55 AbbVie shares in Q2 2026, an estimated $11.8K.
  • AbbVie made up 0.6% of Corundum Group's portfolio in Q2 2026, its #39 holding.
  • Corundum Group first reported a position in AbbVie in Q2 2020 and has held it in 25 quarters since.
  • 4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Corundum Group's 13F filing for Q2 2026, filed 7 Aug 2026.